Balyasny Asset Management
SANA icon

Balyasny Asset Management’s Sana Biotechnology SANA Stock Holding History

Balyasny Asset Management’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,033,804
Closed -$2.98M – 3438
2026
Q1 		$2.98M Sell
1,033,804
-645,326
-38% -$2.54M ﹤0.01% 1600
2025
Q4 		$6.83M Buy
+1,679,130
New +$7.52M 0.01% 1223
2025
Q2 		– Sell
-354,238
Closed -$595K – 3283
2025
Q1 		$595K Buy
+354,238
New +$990K ﹤0.01% 2213
2024
Q4 		– Sell
-18,873
Closed -$78.5K – 3197
2024
Q3 		$78.5K Buy
+18,873
New +$99.1K ﹤0.01% 2638

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

Balyasny Asset Management's SANA Position: Q2 2026 in Review

Balyasny Asset Management sold out of Sana Biotechnology (SANA) in Q2 2026, closing a stake of 1,033,804 shares — an estimated $2.98M sold.

Balyasny Asset Management first reported a position in SANA in Q3 2024 and held it in 4 quarters. The position peaked at $6.83M in Q4 2025. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • Balyasny Asset Management reported no remaining Sana Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 1,033,804 Sana Biotechnology shares in Q2 2026, an estimated $2.98M.
  • Balyasny Asset Management first reported a position in Sana Biotechnology in Q3 2024 and held it in 4 quarters.
  • Balyasny Asset Management's Sana Biotechnology position peaked at $6.83M in Q4 2025.
  • 211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.